304 related articles for article (PubMed ID: 34721025)
1. Beta-Adrenergic Blockade in Critical Illness.
Bruning R; Dykes H; Jones TW; Wayne NB; Sikora Newsome A
Front Pharmacol; 2021; 12():735841. PubMed ID: 34721025
[TBL] [Abstract][Full Text] [Related]
2. β-blockade protection of bone marrow following trauma: the role of G-CSF.
Baranski GM; Offin MD; Sifri ZC; Elhassan IO; Hannoush EJ; Alzate WD; Rameshwar P; Livingston DH; Mohr AM
J Surg Res; 2011 Oct; 170(2):325-31. PubMed ID: 21571320
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic response to β-blockers in severe sepsis and septic shock: A review of current literature.
van Loon LM; van der Hoeven JG; Lemson J
J Crit Care; 2019 Apr; 50():138-143. PubMed ID: 30540967
[TBL] [Abstract][Full Text] [Related]
4. Beta-blocker exposure in patients with severe traumatic brain injury (TBI) and cardiac uncoupling.
Riordan WP; Cotton BA; Norris PR; Waitman LR; Jenkins JM; Morris JA
J Trauma; 2007 Sep; 63(3):503-10; discussion 510-1. PubMed ID: 18073593
[TBL] [Abstract][Full Text] [Related]
5. Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis.
Suzuki T; Suzuki Y; Okuda J; Kurazumi T; Suhara T; Ueda T; Nagata H; Morisaki H
J Intensive Care; 2017; 5():22. PubMed ID: 28270914
[TBL] [Abstract][Full Text] [Related]
6. Ultra-Short-Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients.
Poveda-Jaramillo R; Monaco F; Zangrillo A; Landoni G
J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1415-1425. PubMed ID: 29398384
[TBL] [Abstract][Full Text] [Related]
7. Beta-adrenoreceptor modulation of metabolic, endocrine and immunologic function during critical illness.
Barnes SJ; Ackland GL
Endocr Metab Immune Disord Drug Targets; 2010 Sep; 10(3):292-300. PubMed ID: 20597845
[TBL] [Abstract][Full Text] [Related]
8. Beta-blocker use in severe sepsis and septic shock: a systematic review.
Sanfilippo F; Santonocito C; Morelli A; Foex P
Curr Med Res Opin; 2015; 31(10):1817-25. PubMed ID: 26121122
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study.
Levy B; Fritz C; Piona C; Duarte K; Morelli A; Guerci P; Kimmoun A; Girerd N
Crit Care; 2021 Jan; 25(1):21. PubMed ID: 33413583
[TBL] [Abstract][Full Text] [Related]
10. [Experts consensus on the management of the right heart function in critically ill patients].
Wang XT; Liu DW; Zhang HM; Long Y; Guan XD; Qiu HB; Yu KJ; Yan J; Zhao H; Tang YQ; Ding X; Ma XC; Du W; Kang Y; Tang B; Ai YH; He HW; Chen DC; Chen H; Chai WZ; Zhou X; Cui N; Wang H; Rui X; Hu ZJ; Li JG; Xu Y; Yang Y; Ouyan B; Lin HY; Li YM; Wan XY; Yang RL; Qin YZ; Chao YG; Xie ZY; Sun RH; He ZY; Wang DF; Huang QQ; Jiang DP; Cao XY; Yu RG; Wang X; Chen XK; Wu JF; Zhang LN; Yin MG; Liu LX; Li SW; Chen ZJ; Luo Z;
Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):962-973. PubMed ID: 29202543
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis.
Gore DC; Wolfe RR
Surgery; 2006 May; 139(5):686-94. PubMed ID: 16701103
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
[TBL] [Abstract][Full Text] [Related]
13. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
14. Beta-blockers in septic shock: a review.
Vela-Vásquez RS; Grigorov-Tzenkov I; Aguilar JL
Rev Esp Anestesiol Reanim; 2015 Feb; 62(2):90-5. PubMed ID: 25152109
[TBL] [Abstract][Full Text] [Related]
15. [A Chinese consensus statement on the clinical application of transesophageal echocardiography for critical care (2019)].
Yin WH; Wang XT; Liu DW; Kang Y; Chao YG; Zhang LN; Zhang HM; Wu J; Liu LX; Zhu R; He W; ;
Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):869-882. PubMed ID: 31775449
[TBL] [Abstract][Full Text] [Related]
16. Beta-blocker use is associated with improved outcomes in adult burn patients.
Arbabi S; Ahrns KS; Wahl WL; Hemmila MR; Wang SC; Brandt MM; Taheri PA
J Trauma; 2004 Feb; 56(2):265-9; discussion 269-71. PubMed ID: 14960966
[TBL] [Abstract][Full Text] [Related]
17. [Effects of the β-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study].
Yang S; Liu Z; Yang W; Zhang G; Hou B; Liu J; Shi Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Oct; 26(10):714-7. PubMed ID: 25315942
[TBL] [Abstract][Full Text] [Related]
18. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
19. Timing of resumption of beta-blockers after discontinuation of vasopressors is not associated with post-operative atrial fibrillation in critically ill patients recovering from non-cardiac surgery: A retrospective cohort analysis.
Palm NM; Vallabhajosyula S; Chen A; Lam SW; Weister TJ; Kashani K; Naylor D; Khanna AK
J Crit Care; 2020 Dec; 60():177-182. PubMed ID: 32836092
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of atrial fibrillation in intensive care units and emergency departments].
Arrigo M; Bettex D; Rudiger A
Med Klin Intensivmed Notfmed; 2015 Nov; 110(8):614-20. PubMed ID: 25876744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
